Compare EBON & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBON | CTXR |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | China | United States |
| Employees | N/A | 23 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0M | 18.7M |
| IPO Year | 2020 | 2010 |
| Metric | EBON | CTXR |
|---|---|---|
| Price | $1.86 | $0.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 3.2K | ★ 699.3K |
| Earning Date | 04-24-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $0.47 |
| 52 Week High | $5.90 | $2.19 |
| Indicator | EBON | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 42.86 | 55.70 |
| Support Level | $1.82 | $0.49 |
| Resistance Level | $2.84 | $0.74 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 48.28 | 47.70 |
Ebang International Holdings Inc is engaged in blockchain technology and fintech, with activities also extending to the solar industry, supported by its application-specific integrated circuit (ASIC) chip designs. The Company's business mainly includes the sale of bitcoin mining machines and related accessories, telecommunication products, solar and battery storage products, cryptocurrency exchange services, cross-border payment and foreign exchange services, SaaS data visualization and analytics solutions, and rental services. It generates the majority of its revenue from cross-border payment and foreign exchange services, with its operations mainly in mainland China and Australia, which contribute the maximum revenue.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.